Destiny Pharma plc

Biotech initial public offerings in Europe have been as rare as hen’s teeth in the past few years so the news that Swiss antibiotics specialist BioVersys is looking to list has caught the eye. The Bas

Destiny Pharma plc is set to become the latest UK biotech to bid farewell to the London Stock Exchange’s Alternative Investment Market (AIM) and will take the private route to access cash for its lat

Biotech and pharma companies invest significant resources in the presentation and promotion of their data at medical conferences. This is because wider appreciation of their promising experimental dru

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre